 LA JOLLA, Calif., Nov. 04, 2020 GLOBE NEWSWIRE -- Artelo Biosciences, Inc. NASDAQ: ARTL, a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today reported financial and operating results for the fourth quarter and fiscal year ended August 31, 2020 and provided a business update. 